Advancing Alzheimer's disease drug review as a national priority

Alzheimer's and Dementia

Volumn 5, Issue 2, 2009, Pages 180-181

  Perry, Daniel P ^a  

^a ACT AD Coalition   (United States)

Author keywords

Accelerate Cure Treatments for Alzheimer's Disease; U.S. Food and Drug Administration

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; DISEASE CONTROL; DISEASE SEVERITY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RESEARCH PRIORITY; STANDARDIZATION; TEAMWORK; WORKSHOP;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DRUG APPROVAL; DRUG DESIGN; HEALTH POLICY; HUMANS; PATIENT CARE TEAM; PATIENT SELECTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 62849128805     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2008.08.007     Document Type: Article

References (4)

1. Alzheimer's Association. 2008 Alzheimer's disease facts and figures. Alzheimers Dement 4 (2008) 110-133
2. Herbert L.E., Beckett L.A., Scherr P.A., and Evans D.A. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimers Dis Assoc Disord 15 (2001) 169-173
3. Herbert L.E., Scherr P.A., Bienies J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the United States population: prevalence estimated using the 2000 census. Arch Neurol 60 (2003) 1119-1122
4. Industry estimates on the number of new AD drug candidates and their potential as disease modifying agents is based on information contained in the following subscription databases. NDA Pipeline, FDC Reports, Inc; Investigational Drugs Database (IDdb3), Thomson Scientific, Ltd; Adis R&D Insight, Adis Data Information BV; IMS R&D Focus, IMS Health; and Pharmaprojects, PJB Publications.